Novel Delivery Systems, Unique Pairings Explored With Oncolytic Viruses
Oncoloytic viruses are an emerging class of cancer therapeutics that may provide a new strategy against malignant tumors.
Combining PD-1/PD-L1 Inhibitors and HPV Vaccines Holds Promise in HNSCC
Research on combination therapies involving human papillomavirus-targeted vaccines and immunotherapies continues to expand in phase 2 and 3 trials in patients with head and neck squamous cell carcinoma.
